Search research articles
Contact Us
Filters
Showing results (61-70 of 112) with videos related to
Page
of 12
Sort By:
The Lancet. Oncology
|
May 22, 2007
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study
Cesare Gridelli, Ciro Gallo, Anna Ceribelli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 5, 2010
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials
Massimo Di Maio, Nicola Lama, Alessandro Morabito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2007
Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer
Emanuela Rossi, Alessandro Morabito, Ermelinda De Maio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2010
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study
Giuseppe Colucci, Roberto Labianca, Francesco Di Costanzo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 20, 2017
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial
Alessandro Morabito, Gennaro Daniele, Raffaele Costanzo, et al.
Oncotarget
|
September 17, 2017
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib <i>versus</i> chemotherapy in advanced non-small cell lung cancer patients
Lucia Kim, Mauro Saieg, Massimo Di Maio, et al.
Plos One
|
August 6, 2010
Time spent for activation of non-profit studies in oncology in Italy
Gianfranco De Feo, Simona Signoriello, Jane C Bryce, et al.
BMC Cancer
|
May 14, 2021
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials
Piera Gargiulo, Laura Arenare, Cesare Gridelli, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2009
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials
Cesare Gridelli, Alessandro Morabito, Vittorio Gebbia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2009
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial
Emanuela Rossi, Alessandro Morabito, Francesca Di Rella, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 112) with videos related to
Sort By:
Page
of 12
The Lancet. Oncology
|
May 22, 2007
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study
Cesare Gridelli, Ciro Gallo, Anna Ceribelli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 5, 2010
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials
Massimo Di Maio, Nicola Lama, Alessandro Morabito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2007
Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer
Emanuela Rossi, Alessandro Morabito, Ermelinda De Maio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2010
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study
Giuseppe Colucci, Roberto Labianca, Francesco Di Costanzo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 20, 2017
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial
Alessandro Morabito, Gennaro Daniele, Raffaele Costanzo, et al.
Oncotarget
|
September 17, 2017
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib <i>versus</i> chemotherapy in advanced non-small cell lung cancer patients
Lucia Kim, Mauro Saieg, Massimo Di Maio, et al.
Plos One
|
August 6, 2010
Time spent for activation of non-profit studies in oncology in Italy
Gianfranco De Feo, Simona Signoriello, Jane C Bryce, et al.
BMC Cancer
|
May 14, 2021
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials
Piera Gargiulo, Laura Arenare, Cesare Gridelli, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2009
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials
Cesare Gridelli, Alessandro Morabito, Vittorio Gebbia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2009
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial
Emanuela Rossi, Alessandro Morabito, Francesca Di Rella, et al.
Page
of 12